Lupin has received European Directorate for the Quality of Medicines (EDQM) Attestation of Inspection from EDQM for its Mandideep facility. The unit was inspected by EDQM during March 2018. The inspection was focused on the Application for Certificate of Suitability for the dossier of Cefaclor along with facility inspection for Quality Management Systems based on cGMP as laid under European Union rules governing Medicinal products.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.